Efficacy and tolerability of reboxetine in depressive patients treated in routine clinical practice

CNS Drugs

Volumn 19, Issue 1, 2005, Pages 43-54

  Messer, Thomas ^a   Schmauss, Max ^a   Lambert Baumann, Judith ^b  

^a District Hospital Augsburg   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SOLVEX;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONSTIPATION; DEMOGRAPHY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EVALUATION; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HAMILTON SCALE; HUMAN; INSOMNIA; MALE; MOOD DISORDER; NAUSEA; PRIORITY JOURNAL; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SUBCUTANEOUS FAT DISORDER; SWEATING; SYMPTOMATOLOGY; VOMITING; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEMOGRAPHY; DEPRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PERSONALITY INVENTORY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS; TREATMENT OUTCOME;

EID: 12844267460     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519010-00004     Document Type: Article

References (42)

1. Murray C, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349: 1498-504
2. Hindmarch I, Alford C, Harwell F, et al. Measuring the side effects of psychotropics: the behavioural toxicity of antidepressants. J Psychopharmacol 1992; 6: 198-203
3. Lader M. Tricyclic antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, et al., editors. Antidepressants: past, present and future. Berlin: Springer Verlag, 2004: 185-208
4. Preskorn SH, Ross R, Stanga CY. Selective serotonin reuptake inhibitors. In: Preskorn SH, Feighner JP, Stanga CY, et al., editors. Antidepressants: past, present and future. Berlin: Springer Verlag, 2004: 241-62
5. Baldwin DS, Buis C, Carabal E. Tolerability and safety of reboxetine. Rev Contemp Pharmacother 2000; 11: 321-30
6. Burrows GD, Maguire KP, Normal TR. Antidepressant efficacy and tolerability of the selective noradrenaline reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998; 59 Suppl. 14: S4-7
7. Ferguson JM, Mendels J, Schwartz GE. Effects of reboxetine on Hamilton depression rating scale factors from randomised, placebo-controlled trials in major depression. Int Clin Psychopharmacol 2002; 17: 45-51
8. Hajós M, Fleishaker J, Filipiak-Reisner K, et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004; 1: 23-44
9. Hindmarch I. The effects of antidepressants on psychomotor function with particular reference to reboxetine. Eur Neuropsychopharmacol 1997; 7 Suppl. 1: S17-21
10. Holm KJ, Spencer CM. Reboxetine: a review of its use in depression. CNS Drugs 1999; 12 (1): 65-83
11. Kaspar S. Treatment benefits of reboxetine. Int J Psych Clin Pract 1999; 3 Suppl. 1: S3-8
12. Möller HJ. Klinische Befunde des selektiven Noradrenalin- Wiederaufnahmehemmers Reboxetin. Psychopharmakotherapie 1999; 6 Suppl. 10: 8-10
13. Montgomery SA. Reboxetine: additional benefits to the depressed patients. J Psychopharmacol 1997; 11 Suppl. 4: S9-15
14. Versiani M, Mehilane L, Gaszner P, et al. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999; 60: 400-6
15. Brunello N, Racagni G. Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol 1998; 13: 13-9
16. Racagni G, Brunello N. Physiology to functionality: the brain and neurotransmitter activity. Int Clin Psychopharmacol 1999; 14 Suppl. 1: S3-7
17. Wong EHF, Sonders M, Amara SG, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000; 47: 818-29
18. Szabadi E, Bradshaw CM. Mechanisms of action of reboxetine. Rev Contemp Pharmacother 2000; 11: 267-82
19. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 1998; 13 Suppl.: S29-39
20. Berzewski H, van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997; 7 Suppl. 1: S37-47
21. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997; 11 Suppl. 4: S33-37
22. Avenoso A, Facciola G, Scordo MG, et al. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers. Ther Drug Monit 1999; 21: 577-9
23. Wienkers LC, Allievi C, Hauer MJ, et al. Cytochrome P-450 mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999; 27: 1334-40
24. Leonard BE. The role of noradrenaline in depression: a review. J Psychopharmacol 1997; 11: 39-47
25. Baldwin D, Hawley C, Szabadi E, et al. Reboxetine in the treatment of depression: early clinical experience in the UK. Int J Psych Clin Pract 1998; 2: 195-201
26. Simhandl C, Valenta B. Klinische Erfahrungen der österreichischen Anwendungs beobachtung. Neuropsychiatrie 2002; 16: 159-64
27. Laux G, Schüler P, Bruns S. Edronax® in Klinik und Praxis: Ergebnisse zweier Anwendungsbeobachtungen mit Reboxetin. Psychopharmakotherapie 2000; 7: 162-7
28. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research, 10th rev. Vol. 3. Geneva: World Health Organization, 1994
29. World Health Organization. The ICD-9 classification of mental and behavioural disorders: diagnostic criteria for research. 9th rev. Geneva: World Health Organization, 1978
30. Norwegian Institute of Public Health. Guidelines for ATC classification and DDD assignment. 7th ed. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2003
31. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20 (2): 109-17
32. Brunello N, Mendlewicz J, Kasper S, et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002; 12: 461-75
33. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-22
34. Bondy B. Neurobiochemie, Wirkmechanismus. In: Riederer P, Laux G, Pöldinger W, editors. Neuro-Psychopharmaka Therapie-Handbuch, Band 3. Vienna: Springer Verlag, 2002: 373-8
35. Johnson S, Johnson FN. Reboxetine. Rev Contemp Pharmacother 2000; 11 (5): 257-330
36. Massana J, Möller HJ, Burrows GD, et al. Reboxetine: a double blind comparison with fluoxetine in major depressive disorders. Int Clin Psychopharmacol 1997; 11: 39-47
37. Summary of product characteristics: Solvex®. Frankfurt: Merz Pharmaceutical GmbH, 2003 Jul
38. Reesal RT, Lam RW, and the CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders: II. Principles of management. Can J Psychiatry 2001; 46 Suppl. 1: S21-28
39. Müller MH, Dragicevic A. Standardized rater training for Hamilton Depression rating scale (HAMD-17) in psychiatric novices. J Affect Disord 2003; 77: 65-9
40. O'Sullivan RL, Fava M, Agustin C, et al. Sensitivity of the six-item Hamilton Depression rating scale. Acta Psychiatr Scand 1997; 95: 379-84
41. Demyttenaere K, De Fruyt J. Getting what you ask for: on the selectivity of depression rating scales. Psychother Psychosom 2003; 72: 61-70
42. Kasper S, Möller HJ, Müller-Spahn F. Depression-Diagnose und Pharmakotherapie. 2 Auflage. Stuttgart: Thieme, 2002